OTCPK:IDGX.F

Stock Analysis Report

Integrated Diagnostics Holdings

Executive Summary

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients.

Snowflake

Fundamentals

Solid track record with high growth potential.

Share Price & News

How has Integrated Diagnostics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.8%

OTCPK:IDGX.F

0.1%

US Healthcare

0.8%

US Market


1 Year Return

n/a

OTCPK:IDGX.F

-8.4%

US Healthcare

1.9%

US Market

No trading data on IDGX.F.

No trading data on IDGX.F.


Share holder returns

IDGX.FIndustryMarket
7 Day5.8%0.1%0.8%
30 Day3.1%-1.4%3.4%
90 Day-0.7%-0.7%2.1%
1 Yearn/a-7.0%-8.4%4.2%1.9%
3 Yearn/a30.6%25.3%46.7%37.2%
5 Yearn/a64.9%55.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Integrated Diagnostics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Integrated Diagnostics Holdings undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Integrated Diagnostics Holdings's share price is below the future cash flow value, and at a moderate discount (> 20%).

Integrated Diagnostics Holdings's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Integrated Diagnostics Holdings is overvalued based on earnings compared to the US Healthcare industry average.

Integrated Diagnostics Holdings is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Integrated Diagnostics Holdings is poor value based on expected growth next year.


Price Based on Value of Assets

Integrated Diagnostics Holdings is overvalued based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Integrated Diagnostics Holdings expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

21.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Integrated Diagnostics Holdings's revenue is expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).

Integrated Diagnostics Holdings's earnings are expected to grow significantly at over 20% yearly.

Integrated Diagnostics Holdings's revenue growth is expected to exceed the United States of America market average.

Integrated Diagnostics Holdings's earnings growth is expected to exceed the United States of America market average.

Integrated Diagnostics Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Integrated Diagnostics Holdings is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Integrated Diagnostics Holdings performed over the past 5 years?

33.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Integrated Diagnostics Holdings has delivered over 20% year on year earnings growth in the past 5 years.

Integrated Diagnostics Holdings's 1-year earnings growth is less than its 5-year average (17.1% vs 33.3%)

Integrated Diagnostics Holdings's earnings growth has exceeded the US Healthcare industry average in the past year (17.1% vs 5.6%).


Return on Equity

Integrated Diagnostics Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Integrated Diagnostics Holdings used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

Integrated Diagnostics Holdings has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Integrated Diagnostics Holdings's financial position?


Financial Position Analysis

Integrated Diagnostics Holdings's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Integrated Diagnostics Holdings's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Integrated Diagnostics Holdings's level of debt (5.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0.1% vs 5.3% today).

Debt is well covered by operating cash flow (544%, greater than 20% of total debt).

Integrated Diagnostics Holdings earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 5.9x debt.


Next Steps

Dividend

What is Integrated Diagnostics Holdings's current dividend yield, its reliability and sustainability?

5.12%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Integrated Diagnostics Holdings's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.43%).

Integrated Diagnostics Holdings's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).

Whilst dividend payments have been stable, Integrated Diagnostics Holdings has been paying a dividend for less than 10 years.

Dividend payments have increased, but Integrated Diagnostics Holdings only paid a dividend in the past 3 years.


Current Payout to Shareholders

Dividends paid are not well covered by earnings (1.1x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be covered by earnings (1.3x coverage).


Next Steps

Management

What is the CEO of Integrated Diagnostics Holdings's salary, the management and board of directors tenure and is there insider trading?

4.7yrs

Average board tenure


CEO

Hend El Sherbini (50yo)

7.7yrs

Tenure

ج.م8,392,500

Compensation

Prof. Dr. Hend El Sherbini has been Group Chief Executive Officer of Integrated Diagnostics Holdings plc since 2012 and as its Executive Director since December 23, 2014. Prof. Dr. El Sherbini serves as th ...


CEO Compensation Analysis

Hend's remuneration is lower than average for companies of similar size in United States of America.

Hend's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.


Board Age and Tenure

4.7yrs

Average Tenure

56.5yo

Average Age

The tenure for the Integrated Diagnostics Holdings board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Moushira El Saifi

    Head of Hematology Department

    • Tenure: 0yrs
  • Mohamed Nouh

    Head of Pathology Department and Information Technology Administrator

    • Tenure: 0yrs
  • Osama Zaghloul (59yo)

    Managing Director of Ultralab

    • Tenure: 0yrs
    • Compensation: ج.م176.14k
  • Amid Abdelnour (60yo)

    Managing Director of Biolab

    • Tenure: 0yrs
    • Compensation: ج.م125.00k
  • Eissa Khorshid

    Chief Operating Officer

    • Tenure: 0yrs
  • Hend El Sherbini (50yo)

    Group CEO & Executive Director

    • Tenure: 7.7yrs
    • Compensation: ج.م8.39m
  • Sherif El-Ghamrawi (43yo)

    Investor Relations Director

    • Tenure: 0yrs
  • Tarek Hemida (50yo)

    Group Chief Financial Officer

    • Tenure: 0yrs
    • Compensation: ج.م923.25k
  • Seham Ibrahim (50yo)

    Sales Director

    • Tenure: 0yrs
    • Compensation: ج.م599.24k
  • Mohamed Saleh (37yo)

    General Counsel

    • Tenure: 0yrs

Board Members

  • Anthony St. John Bletso (62yo)

    Independent Non-Executive Chairman

    • Tenure: 4.7yrs
    • Compensation: ج.م1.32m
  • Rick Phillips (54yo)

    Non-Executive Director

    • Tenure: 4.8yrs
  • James Nolan (59yo)

    Independent Non-Executive Director

    • Tenure: 4.4yrs
    • Compensation: ج.م1.06m
  • Hussein Choucri (68yo)

    Independent Non-Executive Director

    • Tenure: 4.7yrs
    • Compensation: ج.م974.28k
  • Hend El Sherbini (50yo)

    Group CEO & Executive Director

    • Tenure: 7.7yrs
    • Compensation: ج.م8.39m
  • Dan Olsson (53yo)

    Independent Non-Executive Director

    • Tenure: 4.7yrs
    • Compensation: ج.م974.28k

Company Information

Integrated Diagnostics Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Integrated Diagnostics Holdings plc
  • Ticker: IDGX.F
  • Exchange: OTCPK
  • Founded: 1979
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$742.500m
  • Shares outstanding: 150.00m
  • Website: https://www.idhcorp.com

Number of Employees


Location

  • Integrated Diagnostics Holdings plc
  • 12 Castle Street
  • Saint Helier
  • JE2 3RT
  • Jersey

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDHCLSE (London Stock Exchange)YesOrdinary SharesGBUSDMay 2015
IDHCLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBUSDMay 2015
IDGX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2015

Biography

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 1,400 diagnostic test services, including immunology,  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 00:41
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.